July MFDS clinical trial medical device Overview
MFDS clinical trial medical device approvals in July 2025 offer a snapshot of Korean regulatory priorities for the pharmaceutical and biotech community. During the month the Ministry of Food and Drug Safety approved 11 investigational device studies, five of them digital or AI‑based. These approvals illustrate the impact of Korea’s Digital Medical Products Act and highlight technologies likely to reach market in coming years.
Digital‑health software
The five software approvals cover critical‑care decision support, behavioural therapy, sepsis prognosis, stroke imaging and renal cancer risk analysis. They range from retrospective validations to randomised exploratory studies, but all seek to prove that algorithmic predictions can augment clinician judgement. For example, one study uses intensive‑care data to estimate 30‑day mortality in septic patients, while another analyses non‑contrast brain CT images to detect cerebral infarcts. A third evaluates abdominal CT analysis for renal cancer risk. Their common goal is to ensure AI tools are accurate, safe and clinically meaningful.
Tissue fillers and biomaterials
Two approvals involve dermal fillers. A single‑centre randomised trial will compare poly‑L‑lactic acid products UREVS PLA and AestheFill‑V200 for temporary nasolabial‑fold correction. Another multicentre non‑inferiority study will test whether new biomaterial JTM104 achieves wrinkle improvement similar to Juvederm® ULTRA PLUS XC without added risks.
Vascular and neural devices
Among vascular approvals, the Prevail drug‑coated balloon will be studied both for in‑stent restenosis and for small‑vessel lesions, and a superiority study will compare percutaneous angioplasty plus the SERVO Stent Graft versus angioplasty alone. HyperQureTM will be evaluated for renal denervation in patients with recurrent atrial fibrillation and resistant hypertension, and VBM‑001 will be tested as a personal low‑frequency stimulator for post‑herpetic neuralgia in a sham‑controlled design.
Trends and implications
July’s approvals show AI and software rapidly permeating medical devices. MFDS is demanding robust data and clinical validation, signaling that developers must build high‑quality datasets and transparent algorithms to gain approval. At the same time, trials of drug‑coated balloons, stent grafts, nerve‑ablating surgical devices and dermal fillers indicate ongoing innovation in traditional hardware. These patterns mirror global regulators’ expectations; harmonization across regions will be vital for companies targeting multiple markets.
An investigational approval is the first step toward commercialization. Results from these 11 trials will influence future regulatory decisions and market dynamics. Companies and researchers should study MFDS trends and integrate regulatory expectations early. For tailored analysis or assistance with clinical strategy, contact us via our [quotation request] page. To stay informed about MFDS approvals and regulatory insights, subscribe to our [newsletter] tailored for professionals in the pharmaceutical and biotechnology sectors.